Anastrozole-associated joint pain and other symptoms in patients with breast cancer

Journal of Pain

Volumn 14, Issue 3, 2013, Pages 290-296

  Shi, Qiuling ^a   Giordano, Sharon H ^a   Lu, Huifang ^a   Saleeba, Angele K ^a   Malveaux, Donna ^a   Cleeland, Charles S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anastrozole; aromatase inhibitor; arthralgia; breast cancer; joint pain; symptoms

Indexed keywords

ANASTROZOLE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BODY MASS; BREAST CANCER; BRIEF PAIN INVENTORY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDUCED DISEASE; FATIGUE; FEMALE; HOT FLUSH; HUMAN; LONGITUDINAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SEXUAL BEHAVIOR; SIDE EFFECT; SLEEP DISORDER; VAGINAL DRYNESS;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ARTHRALGIA; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; MODELS, STATISTICAL; NITRILES; PAIN MEASUREMENT; TRIAZOLES;

EID: 84875206978     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2012.11.010     Document Type: Article

References (20)

1. E. Basch The missing voice of patients in drug-safety reporting N Engl J Med 362 2010 865 869
2. H.J. Burstein Aromatase inhibitor-associated arthralgia syndrome Breast 16 2007 223 234
3. D. Cella, L. Fallowfield, P. Barker, J. Cuzick, G. Locker, and A. Howell Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer Breast Cancer Res Treat 100 2006 273 284
4. C.S. Cleeland, T.R. Mendoza, X.S. Wang, C. Chou, M.T. Harle, M. Morrissey, and M.C. Engstrom Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory Cancer 89 2000 1634 1646
5. C.S. Cleeland Measurement of pain by subjective report C.R. Chapman, J.D. Loeser, Advances in Pain Research and Therapy 1989 Raven Press New York, NY 391 403
6. M. Colleoni, and A. Giobbie-Hurder Benefits and adverse effects of endocrine therapy Ann Oncol 21 2010 vii107 vii111
7. R.C. Coombes, E. Hall, L.J. Gibson, R. Paridaens, J. Jassem, T. Delozier, S.E. Jones, I. Alvarez, G. Bertelli, O. Ortmann, A.S. Coates, E. Bajetta, D. Dodwell, R.E. Coleman, L.J. Fallowfield, E. Mickiewicz, J. Andersen, P.E. Lønning, G. Cocconi, A. Stewart, N. Stuart, C.F. Snowdon, M. Carpentieri, G. Massimini, J.M. Bliss, and C. van de Velde A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081 1092
8. K.D. Crew, J.L. Capodice, H. Greenlee, A. Apollo, J.S. Jacobson, G. Raptis, K. Blozie, A. Sierra, and D.L. Hershman Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients J Cancer Surviv 1 2007 283 291
9. C. Fontaine, A. Meulemans, M. Huizing, C. Collen, L. Kaufman, J. De Mey, C. Bourgain, G. Verfaillie, J. Lamote, R. Sacre, D. Schallier, B. Neyns, J. Vermorken, and J. De Greve Tolerance of adjuvant letrozole outside of clinical trials Breast 17 2008 376 381
10. J. Fransen, G. Stucki, J. Twisk, A.M. Chamot, J.C. Gerster, T. Langenegger, M. Seitz, and B.A. Michel Effectiveness of a measurement feedback system on outcome in rheumatoid arthritis: A controlled clinical trial Ann Rheum Dis 62 2003 624 629
11. N.L. Henry, F. Azzouz, Z. Desta, L. Li, A.T. Nguyen, S. Lemler, J. Hayden, K. Tarpinian, E. Yakim, D.A. Flockhart, V. Stearns, D.F. Hayes, and A.M. Storniolo Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer J Clin Oncol 30 2012 936 942
12. N.L. Henry, J.T. Giles, D. Ang, M. Mohan, D. Dadabhoy, J. Robarge, J. Hayden, S. Lemler, K. Shahverdi, P. Powers, L. Li, D. Flockhart, V. Stearns, D.F. Hayes, A.M. Storniolo, and D.J. Clauw Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors Breast Cancer Res Treat 111 2008 365 372
13. A. Howell, J. Cuzick, M. Baum, A. Buzdar, M. Dowsett, J.F. Forbes, G. Hoctin-Boes, J. Houghton, G.Y. Locker, and J.S. Tobias Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60 62
14. H. Kapstad, B. Rokne, and K. Stavem Psychometric properties of the Brief Pain Inventory among patients with osteoarthritis undergoing total hip replacement surgery Health Qual Life Outcomes 8 2010 148
15. J.J. Mao, C. Stricker, D. Bruner, S. Xie, M.A. Bowman, J.T. Farrar, B.T. Greene, and A. DeMichele Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors Cancer 115 2009 3631 3639
16. M.J. Mourits, E.G. de Vries, P.H. Willemse, K.A. ten Hoor, H. Hollema, and A.G. van der Zee Tamoxifen treatment and gynecologic side effects: A review Obstet Gynecol 97 2001 855 866
17. A.A. Muslimani, T.P. Spiro, A.A. Chaudhry, H.C. Taylor, I. Jaiyesimi, and H.A. Daw Aromatase inhibitor-related musculoskeletal symptoms: Is preventing osteoporosis the key to eliminating these symptoms? Clin Breast Cancer 9 2009 34 38
18. C.A. Presant, L. Bosserman, T. Young, M. Vakil, R. Horns, G. Upadhyaya, B. Ebrahimi, C. Yeon, and F. Howard Aromatase inhibitor-associated arthralgia and/or bone pain: Frequency and characterization in non-clinical trial patients Clin Breast Cancer 7 2007 775 778
19. I. Sestak, J. Cuzick, F. Sapunar, R. Eastell, J.F. Forbes, A.R. Bianco, and A.U. Buzdar Risk factors for joint symptoms in patients enrolled in the ATAC trial: A retrospective, exploratory analysis Lancet Oncol 9 2008 866 872
20. B. Thürlimann, A. Keshaviah, A.S. Coates, H. Mouridsen, L. Mauriac, J.F. Forbes, R. Paridaens, M. Castiglione-Gertsch, R.D. Gelber, M. Rabaglio, I. Smith, A. Wardley, K.N. Price, and A. Goldhirsch A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2005 2747 2757